New Therapeutic Alternatives for the Management of Dyslipidemia
| Autor: | Manouchkathe Cassagnol, Danielle C. Ezzo, Priti N. Patel |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
medicine.medical_specialty Hypercholesterolemia Mipomersen Oligonucleotides Coronary Disease Pharmacology Food and drug administration chemistry.chemical_compound Internal medicine Ezetimibe/atorvastatin medicine Humans Pharmacology (medical) In patient Drug Approval United States Food and Drug Administration business.industry Anticholesteremic Agents medicine.disease United States Coronary heart disease Lomitapide Eicosapentaenoic Acid chemistry Novel agents Benzimidazoles business Dyslipidemia |
| Zdroj: | Journal of Pharmacy Practice. 26:528-540 |
| ISSN: | 1531-1937 0897-1900 |
| DOI: | 10.1177/0897190013507582 |
| Popis: | Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of coronary heart disease (CHD). Conventional therapies, such as statins, have demonstrated their ability to improve clinical end points and decrease morbidity and mortality in patients with CHD. Lomitapide (Juxtapid®), mipomersen (Kynamro®), and icosapent (Vascepa®) are 3 novel agents approved by the US Food and Drug Administration in the past 2 years, which offer new lipid-lowering treatment options with unique pharmacology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|